Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585195 · ClinicalTrials.gov registry record · Phase 1
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 596
- Enrollment target
NCT00585195: Completed Phase 1 study, sponsored by Pfizer.
NCT00585195 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 596 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (893% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00585195, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 596 participants
- Enrollment target
Study Summary
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.
Primary Outcome
MTD: Dose level at which at most 1 of 6 participants experienced DLT within and including 28 days of treatment (during Cycle 1 \[1 cycle=28 days\]) with next higher dose having at least 2/3 or 2/6 participants experiencing a DLT. DLT was defined as any of following: Hematologic toxicities- 1) prolonged grade 4 neutropenia for \>7 days. 2) Febrile neutropenia: grade 4 neutropenia with fever greater than (\>) 38.5 degree Celsius, both sustained over a 24 hour period (3) neutropenic infection: grea
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG PF-02341066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2006-04-19 |
| Est. Completion | 2022-01-19 |
| Phase | Phase 1 |
What the finished NCT00585195 record still lists
NCT00585195 is an interventional study that assigns participants to a tested intervention. The registered 596 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (893% higher).
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT00585195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00585195 about?
NCT00585195 is a clinical study titled "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer". PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine...
What is the current status of trial NCT00585195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 596 participants. The study started on 2006-04-19. Estimated completion is 2022-01-19.
What interventions are being tested in trial NCT00585195?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), PF-02341066 (DRUG).
Who is sponsoring clinical trial NCT00585195?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00585195's enrollment target sits among peer trials
596 28th of 2000 higher than 1,972 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT07100080 · 596 participants · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- NCT05723198 · 595 participants · Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI